Press Releases

Apr 26, 2019

FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization

* Praluent is the first PCSK9 inhibitor that has shown a meaningful reduction in death from any cause
Apr 26, 2019

Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER
- Video 1
- Photos 4
Apr 10, 2019

Sanofi provides unprecedented access to its insulins for one set monthly price

* Sanofi continues its commitment to helping reduce cost burden for people living with diabetes with first-ever insulin savings program
- Photos 1
Mar 22, 2019

FDA issues Complete Response Letter for Zynquista™ (sotagliflozin)
Mar 11, 2019

FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents

* Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis

Show per page